Collaboration will leverage Degron's GlueXplorer® platform to discover novel molecular glue degraders for multiple targets in oncology, neuroscience, and inflammation

合作将利用Degron的GlueXplorer®平台，发现用于肿瘤学、神经科学和炎症多个目标的新型分子胶降解剂

Degron will receive upfront payment and potential milestone payments of up to $1.2 billion

德格隆将收到高达12亿美元的预付款和潜在里程碑付款

Takeda to make equity investment in the company

武田对公司进行股权投资

SAN DIEGO, Calif. and SHANGHAI, China, May 23, 2024 /PRNewswire/ -- Degron Therapeutics ('Degron'), the company using its molecular glue-based targeted protein degradation drug-discovery platform to advance human health, today announced it has entered into a collaboration and exclusive license agreement with Takeda to discover and develop novel molecular glue degraders for multiple targets in oncology, neuroscience, and inflammation..

加利福尼亚州圣地亚哥和中国上海，2024年5月23日/PRNewswire/--Degron Therapeutics（“Degron”），该公司使用其基于分子胶的靶向蛋白质降解药物发现平台来促进人类健康，今天宣布已与武田签订合作和独家许可协议，以发现和开发用于肿瘤学，神经科学和炎症多个目标的新型分子胶降解剂。。

Degron and Takeda will collaborate to utilize Degron's GlueXplorer® platform to identify, validate, and optimize molecular glue degraders for specific therapeutic targets selected by Takeda. Upon reaching a certain stage of advancement, the projects would be transitioned to Takeda for further development and commercialization..

德隆和武田将合作利用德隆的GlueXplorer®平台，为武田选择的特定治疗靶点识别、验证和优化分子胶降解剂。在达到一定的发展阶段后，这些项目将转移到武田进行进一步的开发和商业化。。

'We are excited to collaborate with Takeda, expanding the use of our platform into new therapeutic areas,' said Lily Zou, Ph.D., co-founder and CEO of Degron Therapeutics. 'Degron's differentiated and powerful GlueXplorer platform has been validated by its robust, first-in-class pipeline of novel molecular glue drugs for disease targets that are undruggable by other modalities or better addressed with this new modality.

Degron Therapeutics联合创始人兼首席执行官邹丽丽（Lily Zou）博士说，我们很高兴与武田合作，将平台的使用扩展到新的治疗领域Degron的差异化和强大的GlueXplorer平台已通过其强大的一流新型分子胶药物管道得到验证，这些药物可用于其他方式无法治疗的疾病靶标，或者可以通过这种新方式更好地解决。

By partnering with Takeda, we combine our molecular glue discovery expertise with Takeda's vast drug development and commercialization experience in hopes of offering patients worldwide a new class of treatments.'.

通过与武田合作，我们将我们的分子胶发现专业知识与武田丰富的药物开发和商业化经验相结合，希望为全球患者提供一类新的治疗方法。”。

Under the terms of the agreement, Degron Therapeutics will receive an upfront payment and is eligible to receive potential future preclinical, clinical development and commercial milestone payments that could total $1.2 billion if all related milestones are achieved over the course of the agreement.

根据协议条款，Degron Therapeutics将获得预付款，如果在协议过程中实现所有相关里程碑，则有资格获得未来潜在的临床前，临床开发和商业里程碑付款，总额可能为12亿美元。

Degron is also eligible to receive tiered royalty payments on sales of any potential commercialized products. The parties have the option to expand the collaboration to include more targets. Additionally, Takeda will make an equity investment in Degron. Degron Therapeutics will retain full ownership of its pipeline programs..

德隆也有资格就任何潜在商业化产品的销售收取分层版税。双方可以选择扩大合作，以包括更多目标。此外，武田将对德隆进行股权投资。Degron Therapeutics将保留其管道项目的全部所有权。。

'Molecular glue degraders are a new class of drugs that can be directed at targets previously inaccessible or inadequately modulated by other treatment modalities,' said Chris Arendt, Chief Scientific Officer, Head of Research at Takeda. 'This collaboration with Degron not only adds an innovative new platform to our drug discovery toolbox, it is also an example of cutting-edge innovation emerging in the exciting China biotech sector.'.

武田首席科学官、研究负责人克里斯·阿伦特（ChrisArendt）说：“分子胶降解剂是一类新型药物，可以针对以前无法达到或其他治疗方式调节不足的目标。”与Degron的合作不仅为我们的药物发现工具箱增加了一个创新的新平台，也是令人兴奋的中国生物技术领域新兴的前沿创新的一个例子。”。

Founded in 2021, Degron Therapeutics builds on research from the laboratory of ShanghaiTech University professor and company co-founder Yong Cang, Ph.D. Degron developed a proprietary GlueXplorer platform, which encompasses a unique and expanding library of structurally differentiated molecular glue degraders, multiple complementary screening approaches, and extensive assays to thoroughly validate the molecular glue mechanism for degraders discovered by the platform.

Degron Therapeutics成立于2021年，基于上海理工大学教授和公司联合创始人Yong Cang博士实验室的研究。Degron开发了一个专有的GlueXplorer平台，其中包括一个独特且不断扩展的结构分化分子胶降解物库，多种互补筛选方法，以及广泛的分析方法，以彻底验证平台发现的降解物的分子胶机制。

Degron has generated a large amount of proprietary data and developed an artificial intelligence (AI) algorithm to predict novel molecular glue targets and accelerate compound discovery. Degron has created more than 60 novel diverse cores and 10,000 compounds for its library and a robust pipeline of programs targeting important disease targets including previously undruggable ones across multiple therapeutic areas..

Degron已经产生了大量专有数据，并开发了一种人工智能（AI）算法来预测新型分子胶靶标并加速化合物发现。Degron为其文库创建了60多种新颖的核心和10000种化合物，并针对重要疾病靶标（包括多个治疗领域以前无法治愈的靶标）建立了强大的程序管道。。

About Degron Therapeutics

关于Degron Therapeutics

Degron Therapeutics uses its molecular glue-based targeted protein degradation drug discovery platform to develop novel medicines and advance human health. The company's unique GlueXplorer® platform encompasses a rapidly expanding IP-protected compound library and screening systems to develop a new class of small-molecule medicines that target important disease targets, including those previously undruggable.

Degron Therapeutics使用其基于分子胶的靶向蛋白质降解药物发现平台来开发新药并促进人类健康。该公司独特的GlueXplorer®平台包括一个快速扩展的IP保护化合物库和筛选系统，以开发一类针对重要疾病靶标的新型小分子药物，包括那些以前无法治疗的药物。

The company's pipeline comprises a growing number of preclinical programs for oncology, inflammation, metabolic disorders, and rare diseases. For more information, please visit www.degrontx.com..

该公司的管道包括越来越多的肿瘤，炎症，代谢紊乱和罕见疾病的临床前项目。有关更多信息，请访问www.degrontx.com。。

View original content to download multimedia:https://www.prnewswire.com/news-releases/degron-therapeutics-announces-multi-target-collaboration-and-exclusive-license-agreement-with-takeda-to-discover-molecular-glue-degraders-302152086.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/degron-therapeutics-announces-multi-target-collaboration-and-exclusive-license-agreement-with-takeda-to-discover-molecular-glue-degraders-302152086.html

SOURCE Degron Therapeutics

来源Degron Therapeutics